Parallax Volatility Advisers, L.P. Nektar Therapeutics Transaction History

Parallax Volatility Advisers, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $59,965 - $86,437	4,588 New	4,588 $82,000
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $33,387 - $39,095	-1,077 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $1.41 Million - $2.07 Million	-44,671 Reduced 97.65%	1,077 $36,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $6.77 Million - $12.6 Million	-222,407 Reduced 82.94%	45,748 $1.5 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $213,762 - $315,122	-4,601 Reduced 1.69%	268,155 $16.3 Million

Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $12.6 Million - $28.5 Million	272,739 Added 1604347.0%	272,756 $13.3 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $1.29 Million - $2.44 Million	-22,537 Reduced 99.92%	17 $2,000
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $519,193 - $1.36 Million	22,554	22,554 $1.35 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.